

**Amendments to the Claims under 37 C.F.R. § 1.121**

Claim 1 (currently amended):        A keratinocyte growth factor-2 (KGF-2) protein consisting of:

(a)     residues 63 through 208, 64 through 208, 65 through 208, 66 through 208, 67 through 208, 68 through 208, 70 through 208, 71 through 208, 72 through 208, 73 through 208, 74 through 208, 75 through 208, 76 through 208, 77 through 208, or 78 through 208 of the amino acid sequence set forth in SEQ ID NO: 2; or

(b)     residues 63 through 208, 64 through 208, 65 through 208, 66 through 208, 67 through 208, 68 through 208, 70 through 208, 71 through 208, 72 through 208, 73 through 208, 74 through 208, 75 through 208, 76 through 208, 77 through 208, or 78 through 208 of the amino sequence set forth in SEQ ID NO: 2 and an N-terminal methionine.

Claim 2 (original):    The KGF-2 protein of Claim 1, wherein the amino acid sequence is nonglycosylated.

Claim 3 (original):    The KGF-2 protein of Claim 1, wherein the amino acid sequence is glycosylated.

Claim 4 (original):    A chemical derivative comprising a water-soluble polymer conjugated to the KGF-2 protein of Claim 1.

Claims 5-14 (cancelled).

Claim 15 (previously presented):    A pharmaceutical composition comprising a keratinocyte growth factor-2 (KGF-2) protein isolated from a prokaryotic or eukaryotic host cell comprising a polynucleotide encoding the KGF-2 protein of Claim 1, wherein the host cell is cultured under conditions allowing the expression of the KGF-2 protein, in association with a pharmaceutically acceptable vehicle.

Claim 16 (previously presented): The KGF-2 protein of Claim 1 that is the recombinant expression product of a prokaryotic or eukaryotic host cell comprising an exogenous polynucleotide encoding the KGF-2 protein of Claim 1.

Claim 17 (original): A pharmaceutical composition comprising the KGF-2 protein of Claim 1 in association with a pharmaceutically acceptable vehicle.

Claim 18 (cancelled).

Claim 19 (previously presented): The pharmaceutical composition of Claim 15, wherein the host cell is an E. coli cell, a baculovirus cell, a COS cell, or a Chinese hamster ovary cell.

Claim 20 (original): The KGF-2 protein of Claim 1, wherein at least one domain of the constant region of the heavy chain of human immunoglobulin is fused to the C-terminal end of the KGF-2 protein.

Claim 21 (previously presented): The KGF-2 protein of Claim 1, wherein the KGF-2 protein is fused to a heterologous protein.